XCMR Advances Far UV-C Research at the Second International Congress on Far UV-C Science and Technology
XCMR's CTO Christopher Jones presented groundbreaking research on Far UV-C technology for mitigating Skin and Soft Tissue Infections (SSTIs) at the 2nd International Congress on Far-UVC Science and Technology (ICFUST) 2024.
The research explores the potential of Far UV-C in combating antibiotic resistance and reducing the risk of surgical site infections.
This marks XCMR’s second participation in this prestigious event, highlighting the company’s continued commitment to applying Far UV-C technology to prevent and control skin infection.
The Second International Congress on Far UV-C Science and Technology (ICFUST) 2024, held at the University of St Andrews, Scotland, served as a global platform for researchers, industry leaders, and policymakers to share the latest advancements in Far UV-C technology. The congress aimed to promote responsible deployment of this technology and foster collaborations to address pressing challenges in infection prevention and control.
What XCMR presented
XCMR's CTO, Christopher Jones, presented a poster titled “Investigating Skin and Soft Tissue Infection (SSTI) mitigation using Far UV-C,” co-authored by members of XCMR’s scientific team (C. Jones, D. Mosca, E. Prast, K.G. Linden, E.R. Blatchley, K. Kelley, J. Ducoste, C. Bowers, and B. Robertson.) The poster showcased XCMR’s ongoing research into utilizing Far UV-C light to inactivate a broad spectrum of wound site pathogens, including antibiotic-resistant bacteria.
The research highlighted the potential of Far UV-C as a contactless disinfection method that can be used in conjunction with existing treatments for a multi-layered approach to infection control. The team explored the effectiveness of various Far UV-C sources, including KrCl Excimer, Electron Beam Cathodoluminescence, Pulsed Xenon, and 280nm LED, in reducing MSSA (Methicillin-susceptible Staphylococcus aureus) in both in-vitro and ex-vivo studies.
The presentation also delved into the challenges of real-world wound disinfection, such as occlusion and scattering impacts from fluids, and how XCMR is addressing these through in-silico studies and the development of advanced imaging and modeling techniques.
XCMR’s active participation in the ICFUST 2024 conference for the second time underscores our dedication to pioneering Far UV-C technology for infection prevention and control. Our research on SSTI mitigation highlights the potential of Far UV-C to combat the growing threat of antibiotic resistance and improve patient outcomes.
Looking ahead
XCMR’s research journey doesn't end here. The team is committed to further exploring the potential of the xIP device through ex-vivo testing on porcine and human skin models, incorporating various wound types. The goal is to bridge the gap between laboratory findings and real-world scenarios, ensuring the device's effectiveness in diverse clinical settings. Additionally, in-vivo testing using mouse models will be conducted to evaluate the efficacy and safety of the xIP device in treating SSTIs, bringing this innovative solution one step closer to transforming wound care and infection prevention.
